Business Model Breakdown
How Vanda Pharmaceuticals Inc Makes Money
VNDA
Market Cap
$483M
Annual Revenue
$216M
Profit Margin
-102.0%
Employees
368
The Short Version
Vanda Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders and rare diseases. It primarily generates revenue from the sales of its two commercialized products: Hetlioz, used to treat Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt, prescribed for schizophrenia. The company's future growth strategy is largely centered on the successful development and regulatory approval of its key pipeline candidate, tradipitant, which is currently being investigated for gastroparesis, a significant unmet medical need. Essentially, Vanda aims to discover, develop, and market specialized drugs for niche patient populations.
Where the Revenue Comes From
Sales of Hetlioz (~approx. 60-70% of current revenue, estimated based on past reports, specific % unavailable in current data)
Sales of Fanapt (~approx. 30-40% of current revenue, estimated based on past reports, specific % unavailable in current data)
Potential future revenue from tradipitant
Who buys: Patients diagnosed with Non-24-Hour Sleep-Wake Disorder, Smith-Magenis Syndrome, schizophrenia, and potentially gastroparesis, alongside healthcare providers prescribing these specialized treatments.
Why It Works (Competitive Advantages)
- ✔Potential first-mover advantage with tradipitant in gastroparesis if approved.
- ✔Existing intellectual property and regulatory approvals for Hetlioz and Fanapt.
Economic Moat: None (Intangible Assets/IP (patents for existing drugs and potential tradipitant patent))
What Our Analysis Says
DVR Score as of April 12, 2026
Vanda Pharmaceuticals remains an extremely speculative investment, with its immense 10x growth potential within 3-5 years almost entirely reliant on the successful regulatory approval and robust commercialization of tradipitant for gastroparesis. No material updates on tradipitant's progress have emerged. While existing products provide some revenue, they are insufficient for 10x growth. The lack of recent transparent financial data (margins, balance sheet, cash flow) significantly elevates risk, making fundamental assessment impossible. Furthermore, a 15.25% decline in institutional ownership last quarter signals eroding confidence from major investors. This combination of continued high regulatory risk, financial opacity, and negative institutional sentiment warrants a very low score, reflecting immense speculative upside against considerable and unquantifiable risks.